The Future of Longevity Medicine — Longevity News Roundup — Week 19, 2026

Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine multi-target Alzheimer's therapy, sugar glycation in aging, personalized CRISPR for Parkinson's, Longevity.Technology partnerships, FDA real-time trials, and peptide platforms.Longevity.Technology partners with AND Capital Ventures to combine DLT intelligence platform with funding for healthspan startups. It maps hallmarks, biomarkers, and revenue trajectories to scale longevity firms from data to investment. This scaffolds the ecosystem like oncology, signaling maturation into an asset class.Annovis Bio's Buntanetap oral pill reduces production of multiple neurotoxic proteins like amyloid, tau, and alpha-synuclein by targeting mRNA translation machinery. This upstream approach outperforms single-target amyloid drugs, offering a practical pill over infusions.Estée Lauder research reveals sugar-induced glycation in skin cells triggers inflammation, senescence, and elasticity loss beyond collagen stiffening. Published in International Journal of Molecular Sciences, it links metabolic sugar exposure to systemic aging in vessels and organs. Scribe Therapeutics' CRISPR platform, with STX-1150 data, advances personalized gene editing for Parkinson's, repairing genetic defects in neurons for dopamine restoration. Precise delivery shows strong safety and efficiency signals.FDA pilots real-time cloud-based trials with AstraZeneca and Amgen, streaming data for faster safety signals and approvals. Aimed at accelerating development, it suits longevity's slow endpoints via validated biomarkers like frailty indices. LifespanningRX launches clinician-guided peptide programs for clinics, handling prescriptions, compounding, and shipping amid RFK Jr.-era FDA easing. With $500K funding, it taps recovery and longevity stacks demand via compliant platforms. Raises standards but risks hype without outcome tracking.----------News & References:Longevity.Technology and AND Capital Ventures launch partnership → https://longevity.technology/news/longevity-technology-and-and-capital-ventures-launch-partnership/ Buntanetap gains ground in new Alzheimer’s trial results → https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/Sugar’s hidden role in skin aging revealed → https://longevity.technology/news/sugars-hidden-role-in-skin-aging-revealed/LifespanningRx launches partner program for peptide therapy → https://longevity.technology/news/lifespanningrx-launches-partner-program-for-peptide-therapy/FDA’s real-time trial push could transform medicine – if they work → https://longevity.technology/news/fdas-real-time-trial-push-could-transform-medicine-if-they-work/Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS → https://longevity.technology/news/scribe-highlights-crispr-advances-and-stx-1150-data-at-asgct-eas/